Leveraging Technology to Cut Through the REMS Confusion
The Risk Evaluation and Mitigation Strategies (REMS) program has taken center stage recently as the Food and Drug Administration (FDA), pharmacies and healthcare providers seek ways to improve and streamline its administration. Created in 2007 as part of the FDA Amendments Act, REMS was designed to ensure that the benefits of a drug or biological product outweigh its risks, as well as for post-marketing surveillance of medication safety. While providers agree with these goals, many are also concerned with issues they believe are preventing REMS from achieving its objectives.
You may also like:
The Society of Critical Care Medicine (SCCM) is committed to “Right Care, Right Now.” As part of this commitment, SCCM identifies patient care needs that require evidence-based best practice guidelines and works with expert...
The emergency department provides opportunities to screen for opioid use disorder, provide interventions, and facilitate referral to ongoing treatment. Two published reports (from 2015 and 2017) out of Yale School of Medicine show...
Stay in the Know
Sign up to start receiving notifications via email of our upcoming webinars!